Could a common painkiller boost survival after a deadly aortic tear?

NCT ID NCT06968806

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests whether the anti-inflammatory drug ketorolac can improve outcomes for 360 people undergoing emergency surgery for a severe aortic tear (Stanford Type A aortic dissection). Participants receive either ketorolac or a placebo before and after surgery, alongside standard care. Researchers will track deaths, organ failure, and other serious complications for up to 90 days. The goal is to see if reducing inflammation with ketorolac leads to better recovery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210008, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.